CALIX, INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CALIX, INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $137.90M | Mar 14, 2018 |
| FY2017 | Sep 30, 2017 | $128.83M | Mar 14, 2018 |
| FY2017 | Jul 1, 2017 | $126.12M | Mar 14, 2018 |
| FY2017 | Apr 1, 2017 | $117.52M | Mar 14, 2018 |
| FY2017 | Dec 31, 2016 | $131.80M | Mar 14, 2018 |
| FY2017 | Sep 24, 2016 | $121.19M | Mar 14, 2018 |
| FY2017 | Jun 25, 2016 | $107.43M | Mar 14, 2018 |
| FY2017 | Mar 26, 2016 | $98.38M | Mar 14, 2018 |
| FY2016 | Dec 31, 2015 | $105.00M | Feb 28, 2017 |
| FY2016 | Sep 26, 2015 | $112.30M | Feb 28, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.00B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $831.52M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $1.04B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $867.83M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $679.39M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $541.24M | Feb 21, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $568.32M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $453.59M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $518.32M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $435.43M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $356.59M | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $89.02M | Feb 22, 2021 |
| FY2020 | Sep 26, 2020 | $75.98M | Feb 22, 2021 |
| FY2020 | Jun 27, 2020 | $56.41M | Feb 22, 2021 |
| FY2020 | Mar 28, 2020 | $45.62M | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | $54.71M | Feb 22, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.88M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($29.75M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $29.33M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $41.01M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $238.38M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $33.48M | Feb 21, 2023 |
| FY2012 | Dec 31, 2012 | ($28.33M) | Feb 22, 2013 |
| FY2012 | Dec 31, 2011 | ($52.55M) | Feb 22, 2013 |
| FY2012 | Dec 31, 2010 | ($19.45M) | Feb 22, 2013 |
| FY2011 | Dec 31, 2009 | ($26.19M) | Feb 24, 2012 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.99M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($43.03M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $25.59M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $52.61M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $73.94M | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $24.77M | Feb 22, 2021 |
| FY2020 | Sep 26, 2020 | $21.75M | Feb 22, 2021 |
| FY2020 | Jun 27, 2020 | ($3.34M) | Feb 22, 2021 |
| FY2020 | Mar 28, 2020 | ($6.34M) | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | $1.49M | Feb 22, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $190.36M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $179.87M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $177.77M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $131.99M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $101.75M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $85.26M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $81.18M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $89.96M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $127.54M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $106.87M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $134.95M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $68.40M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $56.25M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $27.18M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $56.79M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $51.41M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $4.65M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $3.56M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | ($62.77M) | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $24.42M | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.44M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $18.05M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $17.86M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $14.07M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $10.46M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $7.82M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $13.35M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $10.43M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $8.03M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $9.84M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.06B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $939.27M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $941.87M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $884.84M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $742.03M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $427.35M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $316.82M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $317.08M | Feb 21, 2020 |
| FY2018 | Jan 1, 2018 | $296.01M | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | $295.07M | Mar 1, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $199.30M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $158.33M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $222.88M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $205.27M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $173.60M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $147.03M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $162.80M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $165.15M | Feb 21, 2020 |
| FY2018 | Jan 1, 2018 | $149.28M | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | $150.11M | Mar 1, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $859.22M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $780.94M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $718.98M | Feb 20, 2026 |
| FY2025 | Dec 31, 2022 | $679.57M | Feb 20, 2026 |
| FY2024 | Dec 31, 2021 | $568.43M | Feb 21, 2025 |
| FY2023 | Dec 31, 2020 | $280.33M | Feb 23, 2024 |
| FY2022 | Dec 31, 2019 | $154.03M | Feb 21, 2023 |
| FY2021 | Dec 31, 2018 | $151.93M | Feb 22, 2022 |
| FY2020 | Dec 31, 2017 | $144.96M | Feb 22, 2021 |
| FY2019 | Dec 31, 2016 | $212.96M | Feb 21, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.18M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $116.18M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $116.18M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $116.18M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $116.18M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $116.18M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $116.18M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $116.18M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $116.18M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $116.18M | Mar 14, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($372.24M) | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | ($390.13M) | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | ($360.38M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | ($389.70M) | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | ($430.71M) | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | ($669.09M) | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | ($702.58M) | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | ($684.88M) | Feb 21, 2020 |
| FY2018 | Jan 1, 2018 | ($665.58M) | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | ($667.36M) | Mar 1, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $143.09M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $43.16M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $63.41M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $79.07M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $51.33M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $80.81M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $46.83M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $49.65M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $39.78M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $50.36M | Mar 14, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Sep 26, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Jun 27, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Mar 28, 2020 | 0 | Feb 22, 2021 |
| FY2021 | Dec 31, 2019 | 0 | Feb 22, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Sep 26, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Jun 27, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Mar 28, 2020 | 0 | Feb 22, 2021 |
| FY2021 | Dec 31, 2019 | 0 | Feb 22, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 67.12M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 66.43M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | 65.05M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | 65.74M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | 64.27M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | 62.12M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | 56.45M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | 53.96M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | 51.51M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 49.39M | Mar 14, 2018 |